EGFR and neoplasm: In comparison to other growth factor receptor pathway inhibitors, e.g., Osimertinib against EGFR, agents targeting FGFRs seem have a lower overall potency, which indicates that tumor cells may be less addicted to complex FGFR signaling pathways with their multiple redundancies.